Trial Profile
Real Life Dosing Regimen of Remicade [infliximab] in Austria, Monitored Over 9 Consecutive Infusions in Rheumatoid Arthritis Therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 Oct 2010 Actual end date (Jul 2010) added as reported by ClinicalTrials.gov.
- 19 Aug 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov